Efavirenz Completed Phase 3 Trials for Human Immunodeficiency Virus (HIV) Infections Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00727597A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
NCT00158470Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)
NCT00158457Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)
NCT00280969Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment
NCT01195467Atripla to Raltegravir Switch Study for CNS Toxicity
NCT01451333The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
NCT00053638A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
NCT00102960Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
NCT00118898Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
NCT00234091When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
NCT00369941A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
NCT00573001Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
NCT01011413Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.
NCT00196612Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
NCT00314626Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
NCT00158821Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
NCT00158405Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)
NCT00135382Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
NCT00135369Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen
NCT00002220Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
NCT00002230A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
NCT00002393A Study of Indinavir Taken With or Without DMP 266
NCT00002447A Study to Compare Two Anti-HIV Drug Combinations
NCT00002448A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
NCT00000903Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen
NCT00075907Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
NCT00112047Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
NCT00013520Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
NCT00013897A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
NCT00005918Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
NCT00050895Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
NCT00028327Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
NCT00006154A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection